Verdad Advisers’s Cogent Biosciences COGT Stock Holding History

Verdad Advisers’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205K	Buy	+5,329	New	+$197K	0.23%	132

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Verdad Advisers's COGT Position: Q1 2026 in Review

Verdad Advisers opened a new position in Cogent Biosciences (COGT) in Q1 2026: 5,329 shares worth $205K. The stake represents 0.23% of the portfolio and ranks #132 among its holdings.

305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Verdad Advisers held 5,329 shares of Cogent Biosciences worth $205K as of Q1 2026.
Cogent Biosciences was a new Verdad Advisers position in Q1 2026.
Cogent Biosciences made up 0.23% of Verdad Advisers's portfolio in Q1 2026, its #132 holding.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.